• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

The effect of direct-acting antivirals on hepatocellular carcinoma recurrence: still waiting for the turning point.

作者信息

Serviddio Gaetano, Villani Rosanna

机构信息

Liver Unit, Centro Universitario per la Ricerca e la cura delle Epatopatie (C.U.R.E.), Department of Medical and Surgical Sciences, University of Foggia, Foggia, Italy.

出版信息

Hepatobiliary Surg Nutr. 2019 Oct;8(5):525-526. doi: 10.21037/hbsn.2019.05.09.

DOI:10.21037/hbsn.2019.05.09
PMID:31673546
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6791973/
Abstract
摘要

相似文献

1
The effect of direct-acting antivirals on hepatocellular carcinoma recurrence: still waiting for the turning point.直接作用抗病毒药物对肝细胞癌复发的影响：仍在等待转折点。
Hepatobiliary Surg Nutr. 2019 Oct;8(5):525-526. doi: 10.21037/hbsn.2019.05.09.
2
Direct-acting antiviral therapy decreases hepatocellular carcinoma recurrence rate in cirrhotic patients with chronic hepatitis C.直接作用抗病毒疗法可降低丙型肝炎肝硬化患者肝癌复发率。
Liver Int. 2017 Aug;37(8):1122-1127. doi: 10.1111/liv.13456. Epub 2017 May 25.
3
Secondary prophylaxis of hepatocellular carcinoma: the comparison of direct-acting antivirals with pegylated interferon and untreated cohort.肝细胞癌的二级预防：直接抗病毒药物与聚乙二醇干扰素及未治疗队列的比较
J Viral Hepat. 2017 Jan;24(1):13-16. doi: 10.1111/jvh.12651. Epub 2016 Dec 1.
4
Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study.直接作用抗病毒治疗后慢性丙型肝炎患者的临床结局：一项前瞻性队列研究。
Lancet. 2019 Apr 6;393(10179):1453-1464. doi: 10.1016/S0140-6736(18)32111-1. Epub 2019 Feb 11.
5
Early development of de novo hepatocellular carcinoma after direct-acting agent therapy: Comparison with pegylated interferon-based therapy in chronic hepatitis C patients.直接作用抗病毒药物治疗后新发肝细胞癌的早期发生：与慢性丙型肝炎患者聚乙二醇干扰素治疗的比较
J Viral Hepat. 2018 Oct;25(10):1189-1196. doi: 10.1111/jvh.12918. Epub 2018 May 17.
6
Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals.直接作用抗病毒药物治疗的丙型肝炎相关肝硬化中肝细胞癌的早期发生和复发。
J Hepatol. 2016 Oct;65(4):727-733. doi: 10.1016/j.jhep.2016.06.015. Epub 2016 Jun 24.
7
Should we cure hepatitis C virus in patients with hepatocellular carcinoma while treating cancer?我们是否应该在治疗肝癌的同时治愈丙型肝炎病毒？
Liver Int. 2018 Dec;38(12):2108-2116. doi: 10.1111/liv.13918. Epub 2018 Jul 21.
8
Use of direct-acting antivirals for hepatitis C viral infection and association with intrahepatic cholangiocarcinoma: Is there a linkage?直接作用抗病毒药物用于丙型肝炎病毒感染及其与肝内胆管癌的关联：是否存在联系？
J Oncol Pharm Pract. 2019 Oct;25(7):1743-1748. doi: 10.1177/1078155218800147. Epub 2018 Sep 26.
9
Lack of evidence of an effect of direct-acting antivirals on the recurrence of hepatocellular carcinoma: Data from three ANRS cohorts.直接作用抗病毒药物对肝细胞癌复发影响的证据不足：来自三个法国国家研究署队列的数据。
J Hepatol. 2016 Oct;65(4):734-740. doi: 10.1016/j.jhep.2016.05.045. Epub 2016 Jun 7.
10
Dropout rate from the liver transplant waiting list because of hepatocellular carcinoma progression in hepatitis C virus-infected patients treated with direct-acting antivirals.
Liver Transpl. 2017 Dec;23(12):1628-1629. doi: 10.1002/lt.24962.

引用本文的文献

1
Lipid Metabolism in Development and Progression of Hepatocellular Carcinoma.脂质代谢在肝细胞癌发生发展中的作用
Cancers (Basel). 2020 May 31;12(6):1419. doi: 10.3390/cancers12061419.

本文引用的文献

1
Time association between hepatitis C therapy and hepatocellular carcinoma emergence in cirrhosis: Relevance of non-characterized nodules.丙型肝炎治疗与肝硬化中肝细胞癌发生的时间关联：非特征性结节的相关性。
J Hepatol. 2019 May;70(5):874-884. doi: 10.1016/j.jhep.2019.01.005. Epub 2019 Jan 24.
2
International incidence and mortality trends of liver cancer: a global profile.全球肝癌发病率和死亡率趋势：国际概况。
Sci Rep. 2017 Mar 31;7:45846. doi: 10.1038/srep45846.
3
DAAs Rapidly Reduce Inflammation but Increase Serum VEGF Level: A Rationale for Tumor Risk during Anti-HCV Treatment.直接抗病毒药物可迅速减轻炎症，但会升高血清血管内皮生长因子水平：抗丙型肝炎病毒治疗期间肿瘤风险的一个理论依据。
PLoS One. 2016 Dec 20;11(12):e0167934. doi: 10.1371/journal.pone.0167934. eCollection 2016.
4
Cancer and liver cirrhosis: implications on prognosis and management.癌症与肝硬化：对预后及治疗的影响
ESMO Open. 2016 Mar 17;1(2):e000042. doi: 10.1136/esmoopen-2016-000042. eCollection 2016.
5
Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals.直接作用抗病毒药物治疗的丙型肝炎相关肝硬化中肝细胞癌的早期发生和复发。
J Hepatol. 2016 Oct;65(4):727-733. doi: 10.1016/j.jhep.2016.06.015. Epub 2016 Jun 24.
6
Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy.接受无干扰素治疗的丙型肝炎相关 HCC 患者早期肿瘤复发率高。
J Hepatol. 2016 Oct;65(4):719-726. doi: 10.1016/j.jhep.2016.04.008. Epub 2016 Apr 13.
7
Risk of hepatocellular carcinoma after sustained virological response in Veterans with hepatitis C virus infection.丙型肝炎病毒感染退伍军人持续病毒学应答后发生肝细胞癌的风险
Hepatology. 2016 Jul;64(1):130-7. doi: 10.1002/hep.28535. Epub 2016 Apr 19.
8
All-Cause Mortality and Progression Risks to Hepatic Decompensation and Hepatocellular Carcinoma in Patients Infected With Hepatitis C Virus.所有原因死亡率和进展为肝性失代偿和肝细胞癌的风险在感染丙型肝炎病毒的患者中。
Clin Infect Dis. 2016 Feb 1;62(3):289-297. doi: 10.1093/cid/civ860. Epub 2015 Sep 28.
9
Meta-analysis: interferon improves outcomes following ablation or resection of hepatocellular carcinoma.荟萃分析：干扰素改善肝癌消融或切除术的疗效。
Aliment Pharmacol Ther. 2010 Oct;32(7):851-8. doi: 10.1111/j.1365-2036.2010.04414.x.
10
Association between hepatitis C and hepatocellular carcinoma.丙型肝炎与肝细胞癌之间的关联。
J Glob Infect Dis. 2009 Jan;1(1):33-7. doi: 10.4103/0974-777X.52979.